Effect of Linezolid on Hematologic Recovery in Newly Diagnosed Acute Myeloid Leukemia Patients Following Induction Chemotherapy

Abstract

There were no significant differences in hematologic outcomes in newly diagnosed AML patients who received linezolid for extended gram-positive antimicrobial coverage following induction chemotherapy. This study provides new insight with a primary focus on the effects of hematologic outcomes when using linezolid in a well-defined acute leukemia population. Further study is warranted with larger populations to assess the potential adverse effects linezolid may have in patients with acute leukemia.

Comparison of Empiric Antibiotic Escalation Therapy With Vancomycin (Van) Versus Linezolid (Lin) in Patients With Febrile Neutropenia

“…Also, Jaksic and coworkers and Nedved et al could not find a difference. 10 , 15 In contrast, Kohno et al could show that Lin was given for 10–28 days in case of pneumonia and skin infections, a higher incidence of anaemia and thrombocytopenia than the VAN group. 11 …”

Vancomycin-resistant enterococcus infection in the hematopoietic stem cell transplant recipient: an overview of epidemiology, management, and prevention

“…A retrospective analysis of 43 HSCT and hematologic malignancy patients with VREB (42 due to E. faecium ) treated with either linezolid (n = 29) for a median of 11.5 days or daptomycin (n = 43) for a median of 13.0 days found no significant difference in outcomes or in duration of thrombocytopenia or neutropenia 113 . In a retrospective analysis of patients receiving induction chemotherapy for newly diagnosed acute myelogenous leukemia, the median times to neutrophil recovery in those who received ≥14 days of linezolid or vancomycin were 29 days and 26 days ( P = 0.487), respectively 114 . This was true despite the fact that linezolid was administered for a duration of 27 days compared to 16 days ( P <0.001) of vancomycin administration.…”